Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

“Will My Baby Be OK?” A Qualitative Analysis of Pregnant Women’s Suboxone® Online Forum Posts

“Will My Baby Be OK?” A Qualitative Analysis of Pregnant Women’s Suboxone® Online Forum Posts Background:Intentional or accidental drug-overdose is a leading cause of mortality in U.S. women of child-bearing age. Opioid use during pregnancy is not only associated with maternal overdose, but with low birth weight at term and neonatal abstinence syndrome (NAS). Buprenorphine was approved as a medication for opioid use disorder (MOUD) in the United States in 2002 and is for many women, a preferred treatment option versus methadone. Buprenorphine is relatively safe during pregnancy and is associated with lower rates of NAS than methadone. Given the importance of MOUD during pregnancy, relatively little information exists regarding patients’ questions and concerns about buprenorphine treatment, including the psychological challenges they face.Aims:The purpose of the study was to describe the perinatal concerns of women with opioid use disorder who posted to an online suboxone forum.Methods:Qualitative descriptive design to analyze some 170 posts from mothers with OUD to an online Suboxone® support forum over the period 2016–2021.Results:The analysis of the interview data revealed 4 important themes: (a) Stigma resulting in self-deprecation, low self-esteem, and low self-efficacy; (b) stigma from family members and loved ones; (c) stigma from the medical profession; and (d) stigma from the community at-large (social stigma).Conclusions:There is compelling evidence to emphasize the importance of open communication and support between medical personnel and patients to ensure optimal outcomes for mother and baby. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the American Psychiatric Nurses Association SAGE

“Will My Baby Be OK?” A Qualitative Analysis of Pregnant Women’s Suboxone® Online Forum Posts

Download PDF
9 pages

Loading next page...
 
/lp/sage/will-my-baby-be-ok-a-qualitative-analysis-of-pregnant-women-s-suboxone-GRf9byrixY

References (26)

Publisher
SAGE
Copyright
© The Author(s) 2023
ISSN
1078-3903
eISSN
1532-5725
DOI
10.1177/10783903231166670
Publisher site
See Article on Publisher Site

Abstract

Background:Intentional or accidental drug-overdose is a leading cause of mortality in U.S. women of child-bearing age. Opioid use during pregnancy is not only associated with maternal overdose, but with low birth weight at term and neonatal abstinence syndrome (NAS). Buprenorphine was approved as a medication for opioid use disorder (MOUD) in the United States in 2002 and is for many women, a preferred treatment option versus methadone. Buprenorphine is relatively safe during pregnancy and is associated with lower rates of NAS than methadone. Given the importance of MOUD during pregnancy, relatively little information exists regarding patients’ questions and concerns about buprenorphine treatment, including the psychological challenges they face.Aims:The purpose of the study was to describe the perinatal concerns of women with opioid use disorder who posted to an online suboxone forum.Methods:Qualitative descriptive design to analyze some 170 posts from mothers with OUD to an online Suboxone® support forum over the period 2016–2021.Results:The analysis of the interview data revealed 4 important themes: (a) Stigma resulting in self-deprecation, low self-esteem, and low self-efficacy; (b) stigma from family members and loved ones; (c) stigma from the medical profession; and (d) stigma from the community at-large (social stigma).Conclusions:There is compelling evidence to emphasize the importance of open communication and support between medical personnel and patients to ensure optimal outcomes for mother and baby.

Journal

Journal of the American Psychiatric Nurses Association – SAGE

Published: May 1, 2023

Keywords: opioid-related disorders; pregnant women; buprenorphine; naloxone drug combination; neonatal abstinence syndrome; social stigma

There are no references for this article.